This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer
Source: Fool - Investing News
This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.